Intrapericardial treatment of neoplastic pericardial effusions.
Pericardial effusion and cardiac tamponade are known complications of many advanced malignancies as lung cancer, breast cancer, lymphomas and leukemias. Initial relief can be easily obtained with percutaneous echo-guided pericardiocentesis, without significant mortality and morbidity and well-tolerated even in critically ill patients. Effusion recurrences can be observed, however, in up to 40% of cases if only simple pericardial drainage is performed. Effective management can be obtained by instillation in the pericardial sac of different agents, with sclerosing or cytostatic activity, like tetracyclines, bleomycin, thiotepa or radionuclides. Intrapericardial sclerotherapy is associated to good results in terms of recurrence prevention and survival improvement. Absence of pericardial effusion at 30 days after drainage can be observed in 70 to 90% of all treated patients, without significant variations among different treatments. No significant side effects are observed, with the exclusion of chest pain during tetracyclines instillation. In our opinion pericardiocentesis associated to intrapericardial sclerotherapy with thiotepa is the best compromise in terms of recurrence prevention, tolerability and costs. Real randomized, case-control studies are moreover required to assess the gold standard of malignant pericardial effusions treatment.
Martinoni
A
A
Cardiology Unit, European Institute of Oncology IRCCS, University of Milan, Milan, Italy. alessandro.martinoni@ieo.it
Cipolla
C M
CM
Civelli
M
M
Cardinale
D
D
Lamantia
G
G
Colleoni
M
M
DeBraud
F
F
Susini
G
G
Martinelli
G
G
Goldhirsh
A
A
Fiorentini
C
C
D000970:Antineoplastic Agents / Q000008:administration & dosage; D002305:Cardiac Tamponade / Q000209:etiology / Q000628:therapy*; D006338:Heart Neoplasms / Q000556:secondary* / Q000628:therapy; D006801:Humans; D010490:Pericardial Effusion / Q000209:etiology / Q000628:therapy*; D020519:Pericardiocentesis; D010496:Pericardium / Q000187:drug effects; D015911:Sclerotherapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents